



Universiteit
Leiden
The Netherlands

Hemolytic disease of the fetus and newborn: awareness precedes change

Winter, D.P. de

Citation

Winter, D. P. de. (2026, March 31). *Hemolytic disease of the fetus and newborn: awareness precedes change*. Retrieved from <https://hdl.handle.net/1887/4299998>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4299998>

Note: To cite this publication please use the final published version (if applicable).

HEMOLYTIC DISEASE OF THE FETUS AND NEWBORN

Awareness Precedes Change

Derek P. de Winter

Hemolytic Disease of the Fetus and Newborn: Awareness Precedes Change

© Copyright 2026 – Derek P. de Winter

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photography or recording or any information storage or retrieval system without the written permission of the author.

The research described in this thesis was performed at the Willem-Alexander Children's Hospital, the Department of Pediatrics and at the Department of Obstetrics of the Leiden University Medical Center; the Department of Immunohematology Diagnostic Services, Sanquin Diagnostic Services in Amsterdam.

ISBN: 978-94-6537-105-4

Layout and cover design: Joey Roberts | www.ridderprint.nl

Print: Ridderprint | www.ridderprint.nl

The research described in this thesis was partially supported by Momenta Pharmaceuticals, which was acquired by Johnson & Johnson.

Financial support for printing this thesis was kindly provided by Universitaire Bibliotheken Leiden, the Willem-Alexander Kinderziekenhuis, Leiden University Medical Center, Stichting IDB (Intrauteriene Diagnostiek en Behandeling) and Canon Medical Systems Nederland.

Hemolytic Disease of the Fetus and Newborn: Awareness Precedes Change

proefschrift

ter verkrijging van
de graad van doctor aan de Universiteit Leiden,
op gezag van rector magnificus prof.dr. S. de Rijcke,
volgens besluit van het college voor promoties
te verdedigen op dinsdag 31 maart 2026
klokke 16:00 uur

door
Derek Paul de Winter
geboren te Leiden
in 1996

(CO-)PROMOTORES EN PROMOTIECOMMISSIE

Promotores:

prof. dr. E. Lopriore

prof. dr. M. de Haas

Co-promotor:

dr. E.J.T. Verweij

Leden promotiecommissie:

prof. dr. L. de Ridder

prof. dr. R. Devlieger - *University Hospitals Leuven, Leuven, Belgium*

dr. P.H. Dijk - *University Medical Center Groningen - Beatrix Children's Hospital*

dr. R.G.M. Bredius

Voor Lieke & Willem
Voor mijn ouders

TABLE OF CONTENTS

PART I	OVERVIEW	8
	General introduction and scope of the thesis	11
Chapter 1	History and current standard of postnatal management in hemolytic disease of the fetus and newborn <i>European Journal of Pediatrics, 2023 Dec;182:489–500</i>	29
PART II	EVALUATING OUR CURRENT STANDARDS OF CARE	50
Chapter 2	Hemolytic disease of the fetus and newborn: systematic literature review of the antenatal landscape <i>BMC Pregnancy and Childbirth, 2023 Jan;23:12</i>	53
Chapter 3	Hemolytic disease of the fetus and newborn: rapid review of postnatal care and outcomes <i>BMC Pregnancy and Childbirth, 2023 Oct;23:738</i>	99
PART III	INTERNATIONAL COLLABORATIONS TO ENHANCE OUR UNDERSTANDING	134
Chapter 4	Variations in Antenatal Management and Outcomes in Haemolytic Disease of the Fetus and Newborn: an international, retrospective, observational cohort study <i>The Lancet Haematology, 2024 Dec;11(12):e927-e937</i>	137
Chapter 5	Variations and opportunities in postnatal management of hemolytic disease of the fetus and newborn <i>JAMA Network Open, 2025;8(1):e2454330</i>	183
Chapter 6	How bureaucracy is bleeding science dry: international observational research under the General Data Protection Regulation <i>The Lancet Regional Health - Europe, 2025;49: 101200</i>	219
PART IV	REFINING THE USE OF EXCHANGE TRANSFUSIONS	224
Chapter 7	Use and Waste of Reconstituted Whole Blood Exchange Transfusions: An 11-year National Observational Study <i>The Journal of Pediatrics 2024 Dec:275:114225</i>	227
Chapter 8	Balancing Blood Product Wastage and Patient Safety: Primum Non Nocere <i>The Journal of Pediatrics 2025 Jan:276:114340</i>	245

Chapter 9	Antenatal Risk Estimation For Exchange Transfusions In Neonates With Hemolytic Disease Of The Fetus And Newborn In A Changing Treatment Landscape: A Multicenter, Retrospective Cohort Study <i>Transfusion, 2025 Dec</i>	251
PART V	INNOVATIONS TO IMPROVE DIAGNOSTICS AND MANAGEMENT	270
Chapter 10	IgG-Fc-glycosylation and a novel flowcytometric assay to predict Hemolytic Disease of the Fetus and Newborn <i>Transfusion Medicine and Hemotherapy, 2025 Aug 5;52(5):279-293</i>	273
Chapter 11	Infant Immunity after Nipocalimab in Early-Onset Severe Hemolytic Disease of the Fetus and Newborn <i>NEJM Evidence 2026 Feb;5(2)</i>	305
PART VI	LONG-TERM OUTCOMES TO GUIDE CLINICAL MANAGEMENT STRATEGIES	332
Chapter 12	Long-term neurodevelopmental outcome in haemolytic disease of the foetus and newborn: a randomized controlled trial with darbepoetin <i>The Lancet Haematology, March 2025, E169-E170</i>	335
Chapter 13	Long-Term Neurodevelopment and Key Associated Factors in Children with Haemolytic Disease of the Foetus and Newborn: a 35-year retrospective analysis <i>Submitted</i>	341
PART VII	DISCUSSION	358
	General discussion and future perspectives	361
	Nederlandse samenvatting	383
APPENDICES		395
	List of abbreviations	396
	List of publications	397
	Curriculum vitae	403
	Dankwoord	404